Skip to main content

Advertisement

Table 3 Effective drugs for the reduction of AURKA

From: Potential new biomarkers for endometrial cancer

Cell line Drug Inhibition target Target symbol PTEZ score
Drugs with significant reduction in AURKA expression post treatment
 A375 Ro-4987655 Mitogen-activated protein kinase MEK − 10
 A375 Genz-644282 Topoisomerase I Topo I − 10
 HUES3 OTS-167 Maternal embryonic leucine-zipper kinase MELK − 10
 HUES3 Vorinostat Histone deacetylase HDAC − 10
 A375 Pralatrexate DNA synthesis − 9.838
 MCF7 Epirubicin Topoisomerase II Topo II − 9.471
 HT29 Ro-4987655 Mitogen-activated protein kinase MEK − 9.284
 MCF7 Pralatrexate Metabolic − 9.259
 A375 JNJ-26481585 Histone deacetylase HDAC − 9.206
 HT29 R-547 Cyclin dependent kinase CDK − 8.938
Drugs with an increase in AURKA expression post treatment
 PC3 BIIB-021 Heat shock protein 90 HSP90 6.298
 HT29 NMS-1286937 Polo-like kinase 1 PLK 6.407
 HELA NMS-1286937 Polo-like kinase 1 PLK 6.426
 HT29 Docetaxel Microtubule function 6.458
 HT29 Epothilone-b Microtubule function 6.518
 HT29 Indibulin Microtubule function 6.552
 HELA Dolastatin-10 Microtubule function 6.666
 HELA Volasertib Polo-like kinase 1 PLK 6.732
 HT29 Epothilone-b Microtubule function 6.898
 HELA Combretastatin-A-4 Microtubule function 7.007
  1. PTEZ post-treatment expression z-score